ClinicalTrials.gg
Active, not recruitingNCT06556368DAYBREAKUpdated Nov 5, 2026

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Phase 3 interventional study of Tarcocimab tedromer and Tabirafusp tedromer in Wet Age-related Macular Degeneration, sponsored by Kodiak Sciences Inc. Active, not recruiting at 72 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment

How we know

Updated Nov 5, 2026Primary completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
667
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
34th of 491
667 · median 55
Started
2024
with 23 others
Phase 3
86 of 645
8 open now
Primary completion
2026-09
later than 22 of 124 live
Registered
577th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 34th largest by enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2024, is one of 86 in phase 3, reaches primary completion later than 22 of the 124 other live ones, and was the 577th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)

03

Conditions studied

  • Wet Age-related Macular Degeneration

Keywords

  • Wet AMD
  • KSI-301
  • KSI-501
  • Tarcocimab
  • Tabirafusp
  • Aflibercept
  • Antibody biopolymer conjugate
  • AMD
  • Anti-VEGF
  • Vascular endothelial growth factor
  • Kodiak Sciences
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active, treatment-naïve choroidal neovascularization (CNV) secondary to AMD, including subfoveal, juxtafoveal, and extrafoveal lesions, or retinal angiomatous proliferations (RAP) lesions with a CNV component that affects the central subfield, as evidenced by FA or OCT in the Study Eye at Screening
  • BCVA ETDRS score between 78 and 25 letters (Snellen equivalent \~20/32 and 20/320) inclusive, in the Study Eye at screening and reconfirmed at Day 1.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • BCVA of hand motion or worse in the non-Study Eye or non-physical presence of a non-Study Eye (i.e., monocular)
  • Fibrosis or atrophy of >50% of the lesion size and/or involving the foveal center of the Study Eye at Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
667 participants (actual)

Study arms

  • Experimental
    Tarcocimab tedromer 5 mg (KSI-301)

    Intravitreal injection of tarcocimab tedromer once every 4 weeks for 4 monthly doses followed by individualized dosing every 4 to 24 weeks.

    Drug: Tarcocimab tedromer

  • Experimental
    Tabirafusp tedromer 5 mg (KSI-501)

    Intravitreal injection of tabirafusp tedromer once every 4 weeks for 4 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing)

    Drug: Tabirafusp tedromer

  • Active comparator
    Aflibercept 2 mg

    Intravitreal injection of aflibercept once every 4 weeks for 3 monthly doses followed by every-8-week dosing

    Drug: Aflibercept

Interventions

  • Intravitreal injection

    Also known as: KSI-301

  • DrugTabirafusp tedromer

    Intravitreal injection

    Also known as: KSI-501

  • Intravitreal injection

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity (BCVA)

    Mean change in BCVA from Day 1 to Year 1

    Time frame: Week 48

07

Study locations

72 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2026, 24 months.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 16, 2024
StartActual
Aug 23, 2024
Primary completionActual
Sep 2, 2026was Aug 2026
CompletionEst.
Aug 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Emanuelli Research & Development Center, LLC · Arecibo, Puerto Rico
Show 1 removed
  • Emanuelli Research & Development Center, LLC · Arecibo, Puerto Rico
Nov 5, 2026
Primary completion
Aug 2026→Sep 2, 2026 (actual)
Nov 5, 2026
Enrollment
675 (estimated)→667 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Emanuelli Research & Development Center, LLC · Arecibo, Puerto Rico
    Show 1 removed
    • Emanuelli Research & Development Center, LLC · Arecibo, Puerto Rico
    Primary completion Aug 2026→Sep 2, 2026 (now actual)
    Enrollment 675 (estimated)→667 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06556368
Lead sponsor
Kodiak Sciences Inc
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Aug 23, 2024
Primary completion
Sep 2, 2026
Completion
Aug 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Pablo Velazquez-Martin, MD
study director · Kodiak Sciences Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tarcocimab tedromer

Start the discussion